Cellectis (CLLS) Change in Account Payables (2015 - 2026)
Cellectis (CLLS) posted quarterly Change in Account Payables of -$3.9 million for Q1 2026, up 38.65% year-over-year from -$2.8 million in Q1 2025, and down 856.47% quarter-over-quarter from $510000.0 in Q3 2025.
Analysis
Cellectis (CLLS) Change in Account Payables (2015 - 2026) Analysis & Trends
Cellectis' Change in Account Payables history runs 12 years deep, the most recent figure standing at -$3.9 million for Q1 2026.
- In Q1 2026, Change in Account Payables rose 38.65% year-over-year to -$3.9 million; the TTM figure through Mar 2026 stood at -$9.6 million (down 682.31% YoY), while the FY2024 annual figure was $2.1 million, up 132.59% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$3.9 million, down from $510000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $7.3 million in Q2 2022, with the low at -$6.5 million in Q1 2022.
- The 5-year median for Change in Account Payables is -$106000.0 (2024), against an average of -$663562.5.
- The sharpest annual moves came in 2023 and 2024: Change in Account Payables plunged 200.34% in 2023, then soared 524.47% in 2024.
- Cellectis' Change in Account Payables stood at $1.8 million in 2022, then slumped by 200.34% to -$1.8 million in 2023, then jumped by 268.13% to $3.0 million in 2024, then tumbled by 82.74% to $510000.0 in 2025, then tumbled by 856.47% to -$3.9 million in 2026.
- Business Quant data shows CLLS's Change in Account Payables at -$3.9 million in Q1 2026, $510000.0 in Q3 2025, and $23000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | 3.84 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.84 Mn |
| Mar 31, 2026 | -3.86 Mn |
| Dec 31, 2025 | 2.50 Mn |
| Sep 30, 2025 | 510,000.00 |
| Jun 30, 2025 | 23,000.00 |
| Mar 31, 2025 | -6.29 Mn |
| Dec 31, 2024 | 2.95 Mn |
| Sep 30, 2024 | -235,000.00 |
| Jun 30, 2024 | 5.22 Mn |
| Mar 31, 2024 | -5.89 Mn |
| Dec 31, 2023 | -1.76 Mn |
| Sep 30, 2023 | 2.89 Mn |
| Jun 30, 2023 | -1.23 Mn |
| Mar 31, 2023 | -6.21 Mn |
| Dec 31, 2022 | 1.75 Mn |
| Sep 30, 2022 | 700,000.00 |
| Jun 30, 2022 | 7.27 Mn |
| Mar 31, 2022 | -6.47 Mn |
| Dec 31, 2021 | 2.35 Mn |
| Sep 30, 2021 | -4.50 Mn |